Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monkhorst

Showing results (91-100 of 160) with videos related to

Pageof 16
Sort By:
Cell Transplantation|April 18, 2012
Feasibility of intracoronary GLP-1 eluting CellBead™ infusion in acute myocardial infarctionJaco H Houtgraaf, Renate de Jong, Kim Monkhorst, et al.
Plos Medicine|April 15, 2025
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation studyMilou M F Schuurbiers, Christopher G Smith, Koen J Hartemink, et al.
Oncoimmunology|August 27, 2024
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL productsSuzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
Critical Reviews in Oncology/Hematology|March 8, 2022
Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluationFred H Menko, Kim Monkhorst, Frans B L Hogervorst, et al.
Oncoimmunology|December 5, 2022
<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction TrialMichiel M Smeenk, Judi N A van Diessen, Thierry N Boellaard, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 7, 2023
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centersJob P van Kooten, Cornedine J de Gooijer, Jan H von der Thüsen, et al.
The Journal of Experimental Medicine|April 10, 2020
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in miceJitendra Badhai, Gaurav Kumar Pandey, Ji-Ying Song, et al.
Lung Cancer (Amsterdam, Netherlands)|January 12, 2020
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancerB van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, et al.
Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:
Pageof 16
Cell Transplantation|April 18, 2012
Feasibility of intracoronary GLP-1 eluting CellBead™ infusion in acute myocardial infarctionJaco H Houtgraaf, Renate de Jong, Kim Monkhorst, et al.
Plos Medicine|April 15, 2025
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation studyMilou M F Schuurbiers, Christopher G Smith, Koen J Hartemink, et al.
Oncoimmunology|August 27, 2024
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL productsSuzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
Critical Reviews in Oncology/Hematology|March 8, 2022
Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluationFred H Menko, Kim Monkhorst, Frans B L Hogervorst, et al.
Oncoimmunology|December 5, 2022
<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction TrialMichiel M Smeenk, Judi N A van Diessen, Thierry N Boellaard, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 7, 2023
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centersJob P van Kooten, Cornedine J de Gooijer, Jan H von der Thüsen, et al.
The Journal of Experimental Medicine|April 10, 2020
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in miceJitendra Badhai, Gaurav Kumar Pandey, Ji-Ying Song, et al.
Lung Cancer (Amsterdam, Netherlands)|January 12, 2020
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancerB van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, et al.
Pageof 16